Quarterly report pursuant to Section 13 or 15(d)

Capital Stock - Biotechnology Value Fund Financing - Additional Information (Details)

v3.8.0.1
Capital Stock - Biotechnology Value Fund Financing - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 9 Months Ended
Feb. 28, 2017
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Class Of Warrant Or Right [Line Items]        
Cash proceeds from issuance of common stock and convertible preferred stock $ 24,900 $ 29,959 $ 45  
Preferred stock, stated value   $ 0.05   $ 0.05
Ownership percentage on outstanding shares   18.50%    
Convertible Preferred Stock (as Converted) [Member]        
Class Of Warrant Or Right [Line Items]        
Sale of shares 5,003      
Preferred stock, stated value $ 4,030      
Conversion of preferred stock into registered common stock 1,000      
Preferred stock conversion price per share $ 4.03      
Total number of shares of common stock issued upon conversion 5,003,000      
Percentage of convertible preferred stock conversion blocker provision 19.99%      
Convertible preferred stock voting rights description   Shares of Series X convertible preferred stock will generally have no voting rights, except as required by law and except that the consent of the holders of the outstanding Series X convertible preferred stock will be required to amend the terms of the Series X preferred stock and to approve certain corporate actions.    
Ownership percentage on outstanding shares upon conversion   49.50%    
Preferred shares converted   0    
Fair value of common stock amount exceeded purchase price of convertible preferred stock $ 5,600      
Common Stock [Member]        
Class Of Warrant Or Right [Line Items]        
Sale of shares 1,200,000      
Common stock share price $ 4.03